Lam Research Corporation vs Tilray Brands Inc — how do they compare? Lam Research Corporation trades at $320.17 (market cap $383.63B), while Tilray Brands Inc trades at $4.23 (market cap $524.07M). The key difference: Lam Research Corporation is far larger — about 732× Tilray Brands Inc's market cap, and Lam Research Corporation pays a 0.34% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| LRCX | TLRY | |
|---|---|---|
Market Cap | $383.63B | $524.07M |
Sector | Technology | Health |
52-Week High | $433.33 | $21.00 |
52-Week Low | $94.84 | $4.23 |
Enterprise Value | $382.61B | $621.22M |
Dividend Yield | 0.34% | — |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $306.96, down 2.02% amid semiconductor sector weakness. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $1.47 versus $1.36 expected, continuing a pattern of earnings outperformance. Valuation metrics remain elevated with P/E at 59.22 and P/S at 18.3, reflecting premium pricing for AI-driven growth prospects. Technical indicators show bearish momentum with price testing key support at $306.
Outlook remains positive based on analyst consensus with $393 price target (78% buy ratings), though near-term risks include semiconductor cycle volatility and rich valuations. The company's positioning in AI chip manufacturing equipment and strong cash flow generation ($6.17B operating cash flow in 2025) supports long-term growth potential despite sector headwinds.
TLRY trades at $4.23, down 1.63% with bearish technical signals. The company reported revenue growth to $821.31M in 2025 but faces severe profitability challenges with a net loss of $2.19B and negative margins. Recent expansion includes medical cannabis launches in Panama and strategic acquisitions, while analyst consensus shows cautious sentiment with 65% hold ratings.
The outlook remains challenging due to persistent losses and high debt levels, though expansion initiatives and potential regulatory changes offer long-term opportunities. Key risks include execution on profitability, competitive pressures, and cannabis regulatory uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →